- Home
- CMLS vs EVAX Comparison
CMLS vs EVAX Comparison
Compare CMLS & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMLS
- EVAX
- Stock Information
- Founded
- CMLS 2002
- EVAX 2008
- Country
- CMLS United States
- EVAX Denmark
- Employees
- CMLS N/A
- EVAX N/A
- Industry
- CMLS Broadcasting
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMLS Consumer Discretionary
- EVAX Health Care
- Exchange
- CMLS Nasdaq
- EVAX Nasdaq
- Market Cap
- CMLS 14.5M
- EVAX 16.3M
- IPO Year
- CMLS 1998
- EVAX 2021
- Fundamental
- Price
- CMLS $0.88
- EVAX $2.53
- Analyst Decision
- CMLS Hold
- EVAX Strong Buy
- Analyst Count
- CMLS 2
- EVAX 3
- Target Price
- CMLS N/A
- EVAX $33.33
- AVG Volume (30 Days)
- CMLS 27.1K
- EVAX 6.8M
- Earning Date
- CMLS 02-27-2025
- EVAX 03-26-2025
- Dividend Yield
- CMLS N/A
- EVAX N/A
- EPS Growth
- CMLS N/A
- EVAX N/A
- EPS
- CMLS N/A
- EVAX N/A
- Revenue
- CMLS $829,801,000.00
- EVAX $3,295,000.00
- Revenue This Year
- CMLS N/A
- EVAX $9,039.73
- Revenue Next Year
- CMLS N/A
- EVAX $1.47
- P/E Ratio
- CMLS N/A
- EVAX N/A
- Revenue Growth
- CMLS N/A
- EVAX N/A
- 52 Week Low
- CMLS $0.63
- EVAX $2.22
- 52 Week High
- CMLS $4.71
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- CMLS 50.83
- EVAX 40.91
- Support Level
- CMLS $0.82
- EVAX $2.43
- Resistance Level
- CMLS $0.97
- EVAX $2.80
- Average True Range (ATR)
- CMLS 0.07
- EVAX 0.31
- MACD
- CMLS -0.00
- EVAX 0.07
- Stochastic Oscillator
- CMLS 48.19
- EVAX 16.94
About CMLS Cumulus Media Inc.
Cumulus Media Inc is an audio-first media company delivering content to over a quarter billion people every month wherever and whenever required. It is a radio broadcasting company combining high-quality local programming with iconic, nationally syndicated media, sports, and entertainment brands to deliver premium content choices to its customers and radio stations affiliated with Westwood One network and numerous digital channels. The company's revenue is derived mainly from the sale of local, regional, and national advertising which is broadcast on its radio stations.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.